Bioexcelife
Biological safety is one of the most important parts of medical device compliance under EU MDR.
If a medical device comes into direct or indirect contact with the human body, manufacturers must show that the materials are safe for the intended use. This is where ISO 10993 becomes essential.
ISO 10993 is the international standard series used for the biological evaluation of medical devices. It helps manufacturers assess whether device materials, manufacturing residues, chemicals, or degradation products may create biological risks for patients or users.
In simple words, ISO 10993 helps answer one key question:
Is this medical device biologically safe for its intended use?
Why ISO 10993 Matters Under EU MDR
Under EU MDR, manufacturers cannot rely on simple statements like “the material is biocompatible.”
They must provide scientific evidence.
Notified Bodies expect a clear biological safety strategy that considers the device’s intended purpose, type of body contact, contact duration, material composition, manufacturing process, sterilization method, and possible chemical risks.
This means biological evaluation is not just a testing activity. It is part of the overall risk management process.
A strong ISO 10993 evaluation helps support patient safety, technical documentation, and MDR compliance.
ISO 10993 Is Not Just a Testing Checklist
Many manufacturers make the mistake of treating ISO 10993 as a fixed list of tests.
That approach can lead to unnecessary testing, higher costs, and weak justification.
ISO 10993 follows a risk-based approach. First, the manufacturer must understand the device, its materials, and its contact with the body. Then the biological risks are assessed. After that, existing data, literature, chemical characterization, toxicological assessment, and testing are reviewed to decide what evidence is needed.
For example, a short-term skin-contact device will not need the same evaluation as a long-term implant.
The evaluation must match the actual biological risk.
The Role of BEP and BER
For MDR submissions, manufacturers commonly prepare a Biological Evaluation Plan (BEP) and a Biological Evaluation Report (BER).
The BEP explains the biological evaluation strategy. It defines which biological endpoints are relevant, what evidence will be used, and whether testing or justification is required.
The BER brings all evidence together. It explains whether the device is biologically safe and whether any remaining biological risks are acceptable.
Notified Bodies review these documents carefully.
If the BEP and BER are unclear, outdated, or disconnected from risk management, questions may arise during review.
What Notified Bodies Expect
Notified Bodies expect biological evaluation to be logical, traceable, and scientifically justified.
They want to see that the manufacturer has identified all relevant biological risks and addressed them properly. They also expect alignment between biological evaluation, risk management, material information, sterilization, packaging, shelf life, and clinical use.
If the device uses new materials, has prolonged body contact, or includes substances of concern, the level of scrutiny increases.
In short, Notified Bodies want a strong scientific argument, not a generic statement.
Common Mistakes Manufacturers Make
One common mistake is submitting old biocompatibility reports without checking whether they still match the current device design, material supplier, manufacturing process, or sterilization method.
Another issue is missing chemical characterization or toxicological risk assessment when it is needed.
Manufacturers also face problems when biological evaluation is not linked with the risk management file. Under MDR expectations, biological safety should not be treated as a separate activity. It should be part of the device’s overall safety strategy.
Why Chemical Characterization Matters
Chemical characterization is becoming more important in biological evaluation.
It helps identify chemicals that may leach from device materials during use. These chemicals may come from raw materials, additives, processing aids, sterilization residues, packaging, or degradation products.
Once chemicals are identified, a toxicological risk assessment can help determine whether exposure levels are acceptable.
This approach can reduce unnecessary animal testing and provide stronger scientific justification for biological safety.
ISO 10993 and Risk Management
ISO 10993 is closely connected to risk management.
Biological risks should be identified, evaluated, controlled, and monitored like other device risks. If a biological concern is found, the manufacturer must decide whether additional testing, material change, supplier control, or toxicological justification is needed.
The final conclusion should clearly explain why the device is safe for its intended contact type and duration.
This connection is especially important during Notified Body review.
What MDR Manufacturers Should Do Now
MDR manufacturers should review their biological evaluation strategy early in the technical documentation process.
They should confirm the correct contact category, review material composition, check supplier and process changes, assess sterilization effects, and verify whether existing test reports remain valid.
Most importantly, they should ensure that the BEP, BER, toxicological assessment, and risk management file tell one consistent safety story.
This reduces review questions and improves audit readiness.
Final Thoughts
ISO 10993 is not just about biocompatibility testing.
It is a framework for proving biological safety through a risk-based, scientific, and well-documented approach.
For MDR manufacturers, the goal is not to perform every possible test. The goal is to build a strong biological safety justification that supports patient safety and regulatory compliance.
A well-prepared ISO 10993 file strengthens technical documentation and builds confidence during Notified Body review.
How Bioexcel Can Help
At Bioexcel, we support medical device manufacturers with ISO 10993 biological evaluation, BEP and BER preparation, toxicological risk assessment, chemical characterization strategy, gap review, and MDR technical documentation alignment.
We help ensure your biological safety evidence is clear, compliant, and Notified Body-ready.
Need support with ISO 10993 biological evaluation under MDR? Partner with Bioexcel for a stronger and safer compliance strategy.
